Vandria announced it has closed a second Series A financing round, bringing total funding to $30.7 million (CHF 28.3 million). According to the company, new investors Hevolution Foundation and Dolby Family Ventures joined the round, which aims to advance its lead candidate, VNA‑318, into clinical trials.
The company said VNA‑318 is an oral mitophagy inducer targeting central nervous system (CNS) diseases linked to mitochondrial dysfunction. Vandria claims preclinical data support its potential to clear damaged mitochondria and restore cellular energy balance, offering a new therapeutic approach for age-related neurodegenerative disorders.
According to Vandria, proceeds from the financing will fund a first-in-human clinical study and expand research on additional pipeline candidates. The company said its broader strategy focuses on modulating mitochondrial quality control processes, including mitophagy, to treat diseases driven by cellular energy deficits.
Vandria claims the successful fundraising reflects growing recognition of mitophagy as a therapeutic target and investor confidence in its scientific platform. The company said it has assembled a leadership team with expertise in mitochondrial biology and CNS drug development to guide VNA‑318 through clinical translation.
Vandria also noted it plans to explore further applications of mitophagy modulation beyond CNS disorders, aiming to address a range of chronic diseases linked to mitochondrial decline.
